Omega-3 (EPA/DHA)
Cardiometabolic and inflammation-related outcomes; can support endurance recovery signals; evidence depends on dose and baseline intake.
Stacks containing Omega-3 (EPA/DHA)
Public community stacks that include this ingredient.
Longevity & Metabolic Health Base
Foundational stack aimed at mitochondrial function, insulin sensitivity, and long-term healthspan.
Your personalized stack
Built from your goals and the supplement evidence library. You can edit doses and timing.
Longevity & Heart Health Base
Targets cardiometabolic markers associated with long-term health.
Omega-3 supplementation associated with reductions in cardiovascular events; benefit most consistent at higher EPA+DHA doses (≥2 g/day) and in high-risk populations.
High-dose omega-3 (≥2 g EPA+DHA/day) consistently reduces fasting triglycerides by 15–30% in adults with elevated baseline levels.
Omega-3 PUFA supplementation produced a statistically significant reduction in DOMS (MD −0.93, 95% CI −1.44 to −0.42; p=0.0004) across 12 RCTs, though the effect size fell below the minimal clinically important difference of 1.4 on a 10-point VAS. Low-quality evidence overall.